Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment

Joint Bone Spine

Volumn 83, Issue 3, 2016, Pages 314-317

  Bardin, Thomas ^a,b,c   Chalès, Gérard ^d   Pascart, Tristan ^e   Flipo, René Marc ^e   Korng Ea, Hang ^a,b,c   Roujeau, Jean Claude ^f   Delayen, Aurélie ^g   Clerson, Pierre ^g  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

^e UNIV LILLE   (France)

^f UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^g Orgamètrie biostatistiques   (France)

Author keywords

Allopurinol; Cross reactivity; Febuxostat; Gout; Severe cutaneous adverse reaction (SCAR); Skin reaction

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; ANTIGOUT AGENT;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; COHORT ANALYSIS; DRESS SYNDROME; ECZEMA; ERYTHEMA; FEMALE; FRANCE; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRURITUS; RASH; RETROSPECTIVE STUDY; RISK FACTOR; SKIN MANIFESTATION; TOXIC EPIDERMAL NECROLYSIS; UNIVERSITY HOSPITAL; VESICULAR RASH; DRUG ERUPTIONS; MIDDLE AGED;

AGED; ALLOPURINOL; DRUG ERUPTIONS; FEBUXOSTAT; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84950114511     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.07.011     Document Type: Article

References (30)

1. Zhang, W., Doherty, M., Bardin, T., et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies including Therapeutics (ESCISIT). Ann Rheum Dis 65 (2006), 1312–1324.
2. Khanna, D., Fitzgerald, J.D., Khanna, P.P., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64 (2012), 1431–1446.
3. Reinders, M.K., Haagsma, C., Jansen, T.L., et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis 68 (2009), 892–897.
4. Dalbeth, N., Stamp, L., Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 20 (2007), 391–395.
5. Kim, S.C., Newcomb, C., Margolis, D., et al. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res (Hoboken) 65 (2013), 578–584.
6. Mockenhaupt, M., Viboud, C., Dunant, A., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128 (2008), 35–44.
7. Stamp, L.K., Taylor, W.J., Jones, P.B., et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 64 (2012), 2529–2536.
8. Hande, K.R., Noone, R.M., Stone, W.J., Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76 (1984), 47–56.
9. McInnes, G.T., Lawson, D.H., Jick, H., Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 40 (1981), 245–249.
10. Hoigne, R., Sonntag, M.R., Zoppi, M., et al. Occurrence of exanthema in relation to aminopenicillin preparations and allopurinol. N Engl J Med, 316, 1987, 1217.
11. Ryu, H.J., Song, R., Kim, H.W., et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol 53 (2012), 211–216.
12. Schumacher, H.R. Jr., Becker, M.A., Wortmann, R.L., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59 (2008), 1540–1548.
13. Becker, M.A., Schumacher, H.R., Espinoza, L.R., et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther, 12, 2010, R63.
14. Becker, M.A., Schumacher, H.R. Jr., Wortmann, R.L., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353 (2005), 2450–2461.
15. Registration file, MIOL Febuxostat Risk Management plan v.4.1, 25 Oct 2013.
16. Mauck, M., Taintor, A., Jha, P., Cross-sensitivity of allopurinol and febuxostat-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. J Gen Intern Med 25 (2010), S504–S505.
17. Abeles, A.M., Febuxostat hypersensitivity. J Rheumatol, 39, 2012, 659.
18. ANSM. Lettre aux professionels de santé sur le risque de survenue de réactions d'hypersensibilité grave, incluant le syndrome de Stevens-Johnson et des chocs anaphylactiques aigus lors de la prise d'adénuric(r) (fébuxostat) (15/6/2012). http://.ansm.sante.fr/S-informer/informations-de-securite-Lettres-aux-professionnels-de-sante/Adenuric-R-febuxostat-Risque-de-survenue-de-reaction-d-hypersensibilite-grave-incluant-le-syndrome-de-Stevens-Johnson-et-des-chocs-anaphylactiques-aigus-Lettre-aux-professionnels-de-sante.
19. Wallace, S.L., Robinson, H., Masi, A.T., et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20 (1977), 895–900.
20. Efron, B., The bootstrap and Markov-chain Monte Carlo. J Biopharm Stat 21 (2011), 1052–1062.
21. Richette, P., Clerson, P., Perissin, L., et al. Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis 74 (2014), 142–147.
22. Bardin, T., Flipo, R.M., Richette, P., et al. Gouty patients with history of adverse reaction to allopurinol are not at higher risk of reaction to febuxostat (abstract). Arthritis Rheum 66 (2014), S68–S69.
23. Chohan, S., Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 38 (2011), 1957–1959.
24. Roujeau, J.C., Clinical heterogeneity of drug hypersensitivity. Toxicology 209 (2005), 123–129.
25. Shear, N.H., Spielberg, S.P., Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 82 (1988), 1826–1832.
26. Hyson, C., Sadler, M., Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 24 (1997), 245–249.
27. Hirsch, L.J., Arif, H., Nahm, E.A., et al. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 71 (2008), 1527–1534.
28. Apter, A.J., Kinman, J.L., Bilker, W.B., et al. Is there cross-reactivity between penicillins and cephalosporins?. Am J Med, 119, 2006 354 e11–e19.
29. Strom, B.L., Schinnar, R., Apter, A.J., et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 349 (2003), 1628–1635.
30. Jick, H., Porter, J.B., Potentiation of ampicillin skin reactions by allopurinol or hyperuricemia. J Clin Pharmacol 21 (1981), 456–458.